Lutetium Lu-177 vipivotide tetraxetan
FDA-approved Lu-177 PSMA therapy (Pluvicto).
What it's for
FDA-approved Lu-177 PSMA therapy (Pluvicto).
What it's for
Lutetium Lu-177 vipivotide tetraxetan is a radioligand that binds prostate-specific membrane antigen. Treats PSMA-positive metastatic castration-resistant prostate cancer after androgen-receptors (lock-and-key landing spots on cells) pathway inhibition and taxane therapy as labeled.
What it does for the body
Treats PSMA-positive metastatic castration-resistant prostate cancer after androgen-receptors (lock-and-key landing spots on cells) pathway inhibition and taxane therapy as labeled. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
PSMA binding delivers beta radiation to PSMA-expressing prostate cancer cells and nearby microenvironment. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Lutetium Lu-177 vipivotide tetraxetan has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Sexual research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Lutetium Lu-177 vipivotide tetraxetan — FDA.gov search
- ClinicalTrials.gov search: Lutetium Lu-177 vipivotide tetraxetan — U.S. clinical trials registry
- Drugs@FDA search: Lutetium Lu-177 vipivotide tetraxetan — FDA drug database (if approved)
- PubMed search: Lutetium Lu-177 vipivotide tetraxetan — NCBI PubMed
- PubMed Central search: Lutetium Lu-177 vipivotide tetraxetan — NCBI PMC